Anti TRBC1 antigen binding domains

US11434293B2 · kind B2 · utility

Assignee

• AUTOLUS LIMITED · GB

Inventors

• Shaun Cordoba · London, GB
• Simon Thomas · London, GB
• Shimobi Onuoha · London, GB
• Ram Jha · London, GB
• Wen Chean Lim · London, GB

Key dates

• Filing date: Oct 12, 2021
• Grant date: Sep 6, 2022
• Expiry date: Oct 12, 2041

Classification

• Technology area (CPC G): Physics
• CPC primary: G01N2800/7028
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The present disclosure relates to anti-TRBC1 antigen binding domains characterized by the sequences of the variable chains. The CDRs sequences of the variable chains are: (VH CDR1) GYTFT, (VH CDR2) NPYNDDIQS, (VH CDR3) GAGYNFDGAYRFFDF; and (VL CDR1) RSSQRLVHSNGNTYL, (VL CDR2) RVSNRFP, (VL CDR3) SQSTHVPYT. The claimed humanized antibodies derive from the murine JOVI antibody. Uses in cancer therapy.